Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Glimepiride I.P. 1mg + Voglibose I.P. 0.1mg + Metformin HCL I.P. 500mg Bi-Layered Tablets
Therapeutic Category
Antidiabetic, Diabetic, Endocrinology
Dosage Form
Tablet
Packaging Type
Blister
Packaging
10*10
Price
₹1/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Vogliviga GM1/0.1 Tablet is a triple combination antidiabetic formulation containing Glimepiride 1mg, Voglibose 0.1mg, and Metformin HCl 500mg in a bi-layered tablet form. This formulation provides a synergistic approach to managing type 2 diabetes mellitus. Glimepiride enhances insulin secretion from pancreatic beta cells, Metformin improves insulin sensitivity and decreases hepatic glucose output, while Voglibose delays carbohydrate absorption in the intestine, thereby controlling postprandial glucose spikes. This fixed-dose combination is ideal for patients who need multi-targeted therapy for optimal glycemic control.
Patients may experience gastrointestinal discomfort such as bloating, nausea, flatulence, or mild diarrhea. Hypoglycemia can occur, especially if meals are skipped. Long-term use of Metformin may lead to Vitamin B12 deficiency.
Used for the management of type 2 diabetes mellitus in patients who require combination therapy to control fasting and postprandial blood sugar levels effectively.
Not suitable for patients with type 1 diabetes, severe renal or hepatic impairment, or gastrointestinal disorders. Blood glucose levels should be monitored regularly. Avoid alcohol intake during the treatment. Always follow physician guidance for dose adjustments.
Store in a cool, dry place below 25°C. Protect from direct sunlight and moisture. Keep out of the reach of children.
Composition : Atorvastatin Calcium I.P. 10mg Tablets
Composition : Atorvastatin Calcium I.P. 20mg Tablets
Composition : Atorvastatin Calcium I.P. 40mg Tablets
Composition : Atorvastatin Calcium I.P. 80mg Tablets
Composition : Atorvastatin Calcium I.P. 10mg + Clopidogrel I.P. 75mg Tablets
Composition : Atorvastatin Calcium I.P. 10mg + Fenofibrate I.P. 160mg Tablets
Composition : Dapagliflozin 10mg + Metformin Hydrochloride I.P. 500mg Tablets
Composition : Dapagliflozin 10mg + Metformin Hydrochloride I.P. 1000mg Tablets
Composition : Dapagliflozin Propanediol Monohydrate 10mg + Vildagliptin I.P. 100mg Tablets
Composition : Metformin 1000mg (S.R.) Tablets
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
This triple anti-diabetic combination has strong demand in the diabetes care segment, making it a key prescription product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.
Medical distributors and wholesalers can benefit from consistent demand in type 2 diabetes management, post-meal blood sugar control, insulin resistance, and long-term glycemic control. It is widely prescribed by physicians and diabetologists for patients requiring multi-mechanism therapy.
Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Glimepiride + Voglibose + Metformin HCl Layered Tablets with monopoly rights, quality packaging, competitive pricing, and reliable supply support for distributors and medical agencies.
Wholesalers and medical agencies benefit from strong chronic prescription demand, lifelong therapy usage, and steady monthly repeat sales in diabetes management when partnering with Cafoli Lifecare.
Medical distributors, stockists, wholesalers, and pharma professionals interested in this diabetic formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.